Champions Oncology Receives Accreditation from The Joint Commission

Hackensack, NJ – January 2, 2014 – Champions Oncology (OTC : CSBR) a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that its Baltimore, MD-based laboratory has received accreditation from The Joint Commission.

The Gold Seal of Approval™ from The Joint Commission was preceded by a rigorous inspection process. The approval upholds the exceptional level of patient care for Champions TumorGraft in vivo sensitivity testing platform.

“This is a significant achievement further validating the quality of our testing procedure” said Ronnie Morris, MD, president of Champions Oncology. “Not only does The Joint Commission accreditation confirm our high-level of clinical standards, but enables us to further grow our Personalized Oncology business.”

In addition to The Joint Commission accreditation, Champions is also certified by the Clinical Laboratory Improvement Amendment (“CLIA”) and has received approval from state departments of health, most recently the New York State Department of Health.